BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Pfizer

The U.K. began widespread vaccination Tuesday after becoming the first western country to authorize the vaccine.

U.K. Regulator Warns People With ‘Significant' Allergies To Avoid Pfizer-BioNTech Vaccine

U.K. regulators said Wednesday that people who have a "significant history'' of allergic reactions shouldn't receive the new Pfizer-BioNTech vaccine.

UK investigates possible allergic reactions to Pfizer coronavirus shot

The U.K. regulator has warned people with a history of “significant allergic reactions” not to have the Pfizer–BioNTech COVID-19 vaccine after two health-care workers had adverse reactions on the first day of the rollout.

U.K. regulators warn people with history of ‘significant' allergic reactions not to have Pfizer–BioNTech COVID-19 vaccine, after two adverse reactions

People who have a history of "significant" allergic reactions should not currently receive the coronavirus vaccine developed by Pfizer and BioNTech, the U.K. drug regulator said on Wednesday.

People with a history of 'significant' allergic reactions shouldn't have Pfizer jab, UK regulator warns

AstraZeneca

Biogen

GlaxoSmithKline

Moderna

Sanofi

Buying strong vaccine stocks at the forefront of the scientific race to treat Covid-19 will help any long-term portfolio in 2021. The post The 7 Best Coronavirus Vaccine Stocks Still In The Race For A Cure appeared first on InvestorPlace.

The 7 Best Coronavirus Vaccine Stocks Still In The Race For A Cure

The FDA says the Pfizer Covid vaccine is both safe and effective. CNBC spoke with Pfizer and Moderna trial participants about what side effects you can expect.

The FDA says Pfizer's Covid vaccine is safe and effective. But brace yourself for the second shot, trial participants warn

An all-day regulatory meeting scheduled to take place Thursday is the next step toward the likely authorization of the first COVID-19 vaccine in the U.S.

U.S. inches closer to FDA authorization of first COVID-19 vaccine

The White House on Tuesday claimed that Pfizer is “negotiating in public” on the allocation of the forthcoming coronavirus vaccine and trying to embarrass the U.S. government in an effort to gain market share over its vaccine competitors.

White House claims Pfizer 'negotiating in public' on coronavirus vaccine allocation

Pfizer stock eked out a small gain Tuesday after Food and Drug Administration documents appeared to support authorizing its coronavirus vaccine. An advisory committee will meet Thursday.

Pfizer Stock Rallies As FDA Appears To Support Covid Vaccine Approval

The company's development of a gene-based vaccine should help investors get over a high stock price

BNTX Stock: Buy at the High?

Pfizer Chief Executive Albert Bourla said on Tuesday he expects a "very intense" meeting with a U.S. vaccine advisory panel this week but is counting on the panel of outside experts to sign off on his company's COVID-19 vaccine candidate.

Pfizer CEO confident of getting U.S. advisory panel nod for COVID-19 vaccine

Ninety-year-old Margaret Keenan on Tuesday became the first person in the world to receive the Pfizer-BioNTech vaccine outside of trial conditions.

UK begins rollout of Pfizer's coronavirus vaccine: Here's what you need to know

That conclusion is based on a new, unfiltered look at clinical trial data from the BNT162b2 program.

Pfizer's Coronavirus Vaccine Is 52.4% Effective After First Dose

The COVID-19 vaccine candidate developed by BioNTech and Pfizer Inc. likely has a "favorable safety profile," according to documents published Tuesday by the Food and Drug Administration. In premarket trading on Tuesday, BioNTech's stock was up 1.3%, and shares of Pfizer gained 0.9%.

FDA highlights safety profile of BioNTech/Pfizer vaccine in advance of advisory committee meeting

WASHINGTON (AP) — Documents released by U.S. regulators Tuesday confirmed that Pfizer and BioNTech's COVID-19 vaccine was strongly protective against COVID-19 -- offering the world's first detailed look at the evidence behind the shots.

Pfizer's COVID-19 vaccine data gets positive FDA review

Here's what you need to know about the impact of Covid-19 to navigate the markets today.

FDA Analysis Confirms Safety of Pfizer Vaccine

"Pfizer did offer up an additional allotment ... to the United States government multiple times," Dr. Scott Gottlieb told CNBC.

U.S. declined Pfizer offer for additional Covid vaccine doses, says board member Dr. Scott Gottlieb

The Food and Drug Administration said Tuesday data from Pfizer's coronavirus vaccine trials did not raise any specific safety concerns.

FDA says Pfizer Covid vaccine data did not raise safety concerns.

The Food and Drug Administration is reportedly expected to release detailed data about Pfizer's coronavirus vaccine on Tuesday as regulators consider whether to clear it for emergency use. The data will give the public an in-depth look at how well the vaccine works before the FDA's vaccine committee meets Thursday to consider Pfizer's application for.

FDA to release detailed data on Pfizer's COVID-19 vaccine

CRISPR Therapeutics

Editas Medicine

Eli Lilly

Novo Nordisk

Roche Holding AG

One metric shows that decades of dominance treating diabetes has created unrivaled profitability.

How You Can Profit From the Best-Managed Drugmaker on Earth

The U.K. will receive just 4 million doses of the vaccine being developed by AstraZeneca and the University of Oxford — by year-end — short of the 30 million doses hoped for.

World watches as first person receives Pfizer-BioNTech COVID shot

Novavax

The companies with the biggest gains won't necessarily be those with the highest sales of coronavirus vaccines.

$40 Billion COVID Vaccine Market in 2021: These 3 Stocks Are Likely to Be the Biggest Winners

The UK is the first country to approve Pfizer's vaccine and is beginning its rollout on Tuesday.

COVID-19 vaccine: 90-year-old woman becomes first to receive Pfizer vaccine in UK

Pfizer Inc (NYSE: PFE) has told the outgoing Donald Trump administration that it cannot supply a considerable amount of additional doses of its COVID-19 vaccine to the United States until late June because other countries have hastened to secure the supply, the Washington Post reported Monday. What Happened: The development means that the U.S. government may have difficulty in procurement beyond the 100 million doses it has already secured earlier this year, according to the Post.

Pfizer Tells US It Can't Provide Substantial Extra Doses Before June As Other Countries Have Already Secured Supply: WaPo

A member of a United States Food and Drug Administration committee on vaccines said that the agency could issue an emergency authorization for Pfizer Inc's (NYSE: PFE) COVID-19 vaccine as early as Friday. What Happened: James Hildreth, a member of the Vaccines and Related Biological Products Advisory Committee, said on NBC's “Weekend Today” show that the body would meet on Thursday to review the COVID-19 vaccine developed by Pfizer and its German partner BioNTech SE (NASDAQ: BNTX).

News for BioNTech SE Stock (BNTX)